Table 1 List of approved drugs targeting CTLA-4 and PD-1 (current as May 2019)
From: Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Drug | Brand name | Indication |
|---|---|---|
CTLA-4 blockers | ||
 Ipilimumab | Yervoy | As monotherapy for metastatic melanoma and surgically resectable ‘high-risk’ melanoma (adjuvant setting) |
PD-1 blockers | ||
 Nivolumab | Opdivo | Metastatic melanoma, metastatic non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), classical Hodgkin’s lymphoma, head and neck squamous cell carcinoma (HNSCC), metastatic urothelial carcinoma, hepatocellular carcinoma (HCC), colorectal cancer with MSI-H and MMR aberrations |
 Pembrolizumab | Keytruda | Metastatic melanoma, surgically resectable ‘high-risk melanoma (adjuvant setting), metastatic NSCLC, classical Hodgkin’s lymphoma, primary mediastinal B-cell lymphoma (PMBCL), HNSCC, gastric cancer, solid tumors with MSI-H and MMR aberrations, metastatic urothelial carcinoma, Merkel cell carcinoma, renal cell carcinoma, cervical cancer, hepatocellular carcinoma, |
 Cemiplimab | Libtayo | Metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation |
PD-L1 blockers | ||
 Atezolizumab | Tecentriq | Metastatic urothelial carcinoma, metastatic NSCLC (monotherapy and in combination with chemotherapy), metastatic SCLC (in combination with chemotherapy) and metastatic triple negative breast cancer (in combination with paclitaxel) |
 Avelumab | Bevencio | Merkel cell carcinoma, metastatic urothelial carcinoma |
 Durvalumab | Imfinzi | Metastatic urothelial carcinoma, unresectable stage III NSCLC |
Combination of CTLA-4 and PD-1 blockers | ||
 Ipilimumab plus nivolumab | Yervoy plus Opdivo | Metastatic melanoma, metastatic renal cell carcinoma, colorectal cancer with MSI-H and MMR aberrations |